Gennex Laboratories Limited

GENNEX6

INE509C01026

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:25:44 31/05/2024 BST			5-day change	1st Jan Change
17.16 ^INR	+1.00%		-9.06%	+2.08%

02-14	Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
02-14	Gennex Laboratories Limited Appoints Dr. S. Ch. Dharma Rao as Additional Director (Non- Executive - Non Independent Director)	CI

Gennex Laboratories Limited Receives New 2 Licenses to Manufacture Drugs for Purposes of Examination, Test or Analysis from the Drug Control Administration , Government of Telangana

July 27, 2022 at 09:18 am

Gennex Laboratories Limited informed that the Company has received new 2 Licenses to manufacture drugs for purposes of examination, test or analysis from the Drug Control Administration, Government of Telangana for a period of 3 years from the date of issue for the following products: Fexofenadine HCL and MINOXIDIL.

Latest news about Gennex Laboratories Limited

Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-14	CI
Gennex Laboratories Limited Appoints Dr. S. Ch. Dharma Rao as Additional Director (Non- Executive - Non Independent Director)	02-14	CI
Gennex Laboratories Limited Announces Resignation of Tiruvarur Muralidharan Gopalakrishnan as Whole Time Director	02-01	CI
Gennex Laboratories Gets Good Manufacturing Practices Certificate from Indian Regulator	12-13	MT
Gennex Laboratories Limited announced that it expects to receive INR 966.125 million in funding from Premier Fiscal Services Pvt Ltd	12-01	CI
Gennex Laboratories Board to Consider Raising Funds Via Equity	11-29	MT
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23	CI
Gennex Laboratories Gets Permission to Manufacture, Sell Fexofenadine, Minoxidil	10/08/23	MT
Gennex Laboratories Limited Obtains Approval of Additional Products from Drug Control Administration, Government of Telangana	09/08/23	CI
Gennex Laboratories Gets WHO-GMP Certification from Drug Control Administration, Government of Telangana	11/07/23	MT
Gennex Laboratories Arm Gets Drug Manufacturing License	02/06/23	MT
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023	31/05/23	CI
Gennex Laboratories Limited Appoints Dinesh Kumar Kejriwal as Company Secretary & Compliance Officer	20/04/23	CI
Gennex Laboratories Limited completed the acquisition of 6.73% minority stake in Deccan Remedies Limited.	28/02/23	CI
Gennex Laboratories Limited Approves the Acceptance of Resignation of Rajesh Vankadara as Company Secretary & Compliance Officer	14/02/23	CI
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	14/02/23	CI
Gennex Laboratories Limited Announces Rajesh Vankadara to Resign as Company Secretary & Compliance Officer Effect from February 26, 2023	07/02/23	CI
Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	12/08/22	CI
Gennex Laboratories Limited Receives New 2 Licenses to Manufacture Drugs for Purposes of Examination, Test or Analysis from the Drug Control Administration , Government of Telangana	27/07/22	CI
Gennex Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/05/22	CI
Gennex Laboratories Board OKs Up to $5.3 Million Rights Issue	06/04/22	MT
Gennex Laboratories Board to Consider Fundraising Via Debt or Equity Offering	28/03/22	MT
Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI
Gennex Laboratories Limited agreed to acquire additional 6.73% minority stake in Deccan Remedies Limited.	23/12/21	CI

Chart Gennex Laboratories Limited

Duration

Period

More charts

Company Profile

Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing bulk drugs, intermediaries, and biotech products. The Company has a robust product portfolio spread over major product segments encompassing expectorants, muscle relaxants, analgesic and anti-fungal. The Company operates through the Pharmaceutical Products (Bulk Drugs) segment. The Company's products include active pharmaceutical ingredients, such as Guaifenesin USP/BP/EP/IP, which is an expectorant, (mucolyte); Methocarbamol USP, which is a relaxant (skeletal muscle relaxant); Phenazopyridine Hcl USP, which is an urinary tract analgesic; Fluconazole EP/USP, which is an anti-fungal product; Mephenesin IP/BP, which is a muscle relaxant; Chlorphenesin IP/BP, which is anti-fungal, and Melitracen Hcl, which is an antidepressant. The Company has manufacturing facilities in India which cater to both domestic and international markets.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GENNEX LABORATORIES LIMITED	+2.08%	46.77M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B